Inozyme Pharma (NASDAQ:INZY) Given New $16.00 Price Target at HC Wainwright

Inozyme Pharma (NASDAQ:INZY) had its price objective boosted by HC Wainwright from $14.00 to $16.00 in a research note published on Friday morning,Benzinga reports. The brokerage currently has a buy rating on the stock.

Several other brokerages have also issued reports on INZY. Raymond James assumed coverage on Inozyme Pharma in a report on Thursday, December 12th. They set an “outperform” rating and a $26.00 price objective on the stock. Stifel Nicolaus initiated coverage on Inozyme Pharma in a research report on Thursday, September 12th. They set a “buy” rating and a $16.00 price target on the stock. Wedbush reiterated an “outperform” rating and issued a $12.00 price objective (down previously from $15.00) on shares of Inozyme Pharma in a research note on Tuesday, November 5th. Finally, Needham & Company LLC restated a “buy” rating and set a $23.00 target price on shares of Inozyme Pharma in a research report on Wednesday, November 6th. Eight analysts have rated the stock with a buy rating, Based on data from MarketBeat, Inozyme Pharma has a consensus rating of “Buy” and a consensus target price of $17.25.

Inozyme Pharma Price Performance

INZY stock opened at $2.00 on Friday. The business has a 50 day moving average price of $3.07 and a 200 day moving average price of $4.40. The company has a quick ratio of 7.68, a current ratio of 7.68 and a debt-to-equity ratio of 0.51. The stock has a market cap of $128.48 million, a price-to-earnings ratio of -1.28 and a beta of 1.35. Inozyme Pharma has a fifty-two week low of $1.97 and a fifty-two week high of $7.80.

Inozyme Pharma (NASDAQ:INZY) last issued its quarterly earnings data on Tuesday, November 5th. The company reported ($0.39) earnings per share for the quarter, topping the consensus estimate of ($0.44) by $0.05. Equities research analysts anticipate that Inozyme Pharma will post -1.59 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Inozyme Pharma

Several large investors have recently modified their holdings of the stock. Deerfield Management Company L.P. Series C purchased a new position in Inozyme Pharma in the 2nd quarter valued at $52,000. Virtu Financial LLC acquired a new position in shares of Inozyme Pharma during the third quarter worth about $64,000. Meeder Asset Management Inc. purchased a new position in Inozyme Pharma during the second quarter worth about $68,000. SG Americas Securities LLC acquired a new stake in Inozyme Pharma in the third quarter valued at about $81,000. Finally, Cubist Systematic Strategies LLC purchased a new stake in Inozyme Pharma in the 2nd quarter valued at approximately $84,000. Hedge funds and other institutional investors own 88.30% of the company’s stock.

Inozyme Pharma Company Profile

Inozyme Pharma, Inc, a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis.